Table 3 Treatment characteristics in chronic hepatitis C patients with and without diabetes.
From: Response to therapy with direct antiviral drugs in HCV-infected patients with diabetes
Parameter | All patients (n = 18968) | Diabetic group (n = 2179) | Non-diabetic group (n = 16789) | p-value |
|---|---|---|---|---|
History of antiviral treatment | ||||
Treatment-naive, % (n) | 80.8 (15328) | 73.1 (1593) | 81.8 (13735) | < 0.001 (χ2 = 94.2) |
Non-responder to IFN-based regimens, % (n) | 17.0 (3232) | 24.2 (527) | 16.1 (2705) | < 0.001 (χ2 = 88.9) |
Non-responder to IFN-free regimens, % (n) | 2.2 (408) | 2.7 (59) | 2.1 (349) | 0.057 (χ2 = 3.6) |
Current treatment regimen | ||||
Current-RBV-containing regimens, % (n) | 14.0 (2665) | 22.8 (497) | 12.9 (2168) | < 0.001 (χ2 = 156.4) |
Genotype- specific treatment regimens, % (n) | 52.0 (9871) | 59.9 (1305) | 51.4 (8633) | < 0.001 (χ2 = 22.4) |
ASV + DCV, % (n) | 0.7 (135) | 1.0 (21) | 0.7 (114) | 0.137 (χ2 = 2.2) |
SOF/LDV ± RBV, % (n) | 16.1 (3061) | 19.9 (435) | 15.6 (2626) | < 0.001 (χ2 = 26.6) |
OBV/PTV/r ± DSV ± RBV, % (n) | 21.4 (4064) | 22.2 (483) | 21.3 (3581) | 0.370 (χ2 = 0.8) |
GZR/EBR ± RBV, % (n) | 13.7 (2601) | 13.6 (297) | 13.7 (2304) | 0.905 (χ2 = 0.01) |
SOF + SMV ± RBV, % (n) | 0.1 (10) | 0.1 (2) | 0.1 (8) | 0.322 |
Pangenotypic regimens, % (n) | 48.0 (9097) | 40.1 (874) | 48.6 (8156) | < 0.001 (χ2 = 22.4) |
SOF + RBV, % (n) | 1.8 (344) | 2.7 (59) | 1.7 (285) | 0.001 (χ2 = 11.0) |
SOF + DCV ± RBV, % (n) | 0.2 (46) | 0.4 (8) | 0.2 (38) | 0.209 (χ2 = 1.6) |
GLE/PIB, % (n) | 26.0 (4934) | 16.9 (369) | 27.2 (4565) | < 0.001 (χ2 = 105.4) |
GLE/PIB + SOF + RBV, % (n) | 0.04 (7) | 0 | 0.04 (7) | 1 |
SOF/VEL ± RBV, % (n) | 19.4 (3677) | 22.5 (490) | 19.0 (3187) | < 0.001 (χ2 = 15.2) |
SOF/VEL/VOX, % (n) | 0.5 (89) | 0.7 (15) | 0.4 (74) | 0.111 (χ2 = 2.5) |
